Sorrento Therapeutics (SRNE) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sti-6129 | Light Chain (Al) Amyloidosis | Phase I | Withdrawn | An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis | Jan 11, 2023 | ― |
| Sti-6129 | Advanced Solid Tumor | Phase I | Not Yet Recruiting | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Oct 12, 2022 | ― |
| Sti-9199 | Covid-19 | Phase II | Withdrawn | Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents | May 10, 2022 | ― |
| Sti-1386 | Solid Tumor, Cancer, Sarcoma, Hepatic Metastasis, Cancer Of Pancreas | Phase I | Not Yet Recruiting | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Apr 27, 2022 | ― |
| Sti-1558 | Covid-19 | Phase I | Completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers | Apr 15, 2022 | ― |
| Abiraterone, Abivertinib | Prostate Cancer, Prostate Cancer Metastatic | Phase II | Suspended | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | Apr 15, 2022 | ― |
| Sti-6129 | Multiple Myeloma | phase1AndPhase2 | Active Not Recruiting | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Mar 15, 2022 | ― |
| Covi-Drops | Covid-19 | Phase II | Withdrawn | Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection | Oct 07, 2021 | ― |
| Resiniferatoxin | Pain, Pain, Intractable, Pain Cancer | Phase II | Suspended | Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer | Sep 17, 2021 | ― |
| Sti-3258 | Solid Tumor, Adult, Relapsed Solid Neoplasm, Refractory Cancer | Phase I | Withdrawn | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | Aug 20, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Sti-6129 | Phase I | Light Chain (Al) Amyloidosis | Withdrawn | An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis | Jan 11, 2023 | ― |
| Sti-6129 | Phase I | Advanced Solid Tumor | Not Yet Recruiting | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Oct 12, 2022 | ― |
| Sti-9199 | Phase II | Covid-19 | Withdrawn | Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents | May 10, 2022 | ― |
| Sti-1386 | Phase I | Solid Tumor, Cancer, Sarcoma, Hepatic Metastasis, Cancer Of Pancreas | Not Yet Recruiting | Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors | Apr 27, 2022 | ― |
| Sti-1558 | Phase I | Covid-19 | Completed | Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers | Apr 15, 2022 | ― |
| Abiraterone, Abivertinib | Phase II | Prostate Cancer, Prostate Cancer Metastatic | Suspended | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | Apr 15, 2022 | ― |
| Sti-6129 | phase1AndPhase2 | Multiple Myeloma | Active Not Recruiting | Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma | Mar 15, 2022 | ― |
| Covi-Drops | Phase II | Covid-19 | Withdrawn | Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection | Oct 07, 2021 | ― |
| Resiniferatoxin | Phase II | Pain, Pain, Intractable, Pain Cancer | Suspended | Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer | Sep 17, 2021 | ― |
| Sti-3258 | Phase I | Solid Tumor, Adult, Relapsed Solid Neoplasm, Refractory Cancer | Withdrawn | Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors | Aug 20, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Sorrento Therapeutics Inc (SRNE) have in its pipeline
Sorrento Therapeutics SRNE is currently developing the following drugs: Sti-6129, Sti-9199, Sti-1386, Sti-1558, Abiraterone, Abivertinib, Covi-Drops, Resiniferatoxin, Sti-3258, Sti-1492, Covi-Msc, Sti-6643, Resiniferatoxin, Zilretta, Sti-3031, Covi-Amg, Standard of Care, Resiniferatoxin, Sofusa Doseconnect, Enbrel, Sti-5656, Psc-04, Standard of Care, Covi-Guard, Standard of Care, Abivertinib, Pembrolizumab Administered Using The Sofusa® Doseconnect™, Capecitabine, Anti-Cea Car-T Cells, Gemcitabine/Nab Paclitaxel, Nlir+Fu/Fa, Car2 Anti-Cea Car-T Cells, Anti-Cea Car-T Cells. These drug candidates are in various stages of clinical development as the company works toward FDA approval.